Dr. Scott Rocklage is an academician and an entrepreneur. He is a senior managing member at the distinguished California-based 5 AM Ventures. Together with his wife, Patty Rocklage, the couple is affiliated with many charity organizations. The two also give donations towards empowerment projects, a recent funding of lab renovations at MIT being a case in point.
A former student of the great scientist and chemistry Nobel Laurate, Professor Richard R. Schrock, Dr. Scott turned out to be a science guru as well. He has been in the healthcare sector for a period in excess of 30 years and has made a tangible impact on it. Scott will remain a dominant force for a long time in the industry for playing a vital role in the approval of Teslascan®, Cubicin®, and Omniscan™ drugs by the FDA.
Scott Rocklage puts his extensive experience and academic excellence to good use by being part of many advisory and directorship boards for different organizations. Some of the organizations Scott associates with either as a member or a chair include Epirus, Rennovia, Novira, Cidara, and Relypsa. He has also held management and executive roles at companies, such as Nycomed Salutar, Cubist Pharmaceuticals, and Catalytica. To add to his experience, Scott has been part of invention processes of more than 30 patents.
5 AM Ventures finances early-stage life science research. With the early aspect of its field of operation, the name 5 AM comes in to denote early. Scott Rocklage revealed this during an interview with Ideamensch.
The interview dug deeper to get more to Scott’s personal life. Being a busy person, he was not able to describe exactly how his day typically rolls out. His schedule incorporates board meetings, research, and company management, which means that every day, is always different from the rest.
Scott told Ideamensch that he executes his ideas through a consultative process. He involves professionals from different backgrounds that would be key to the success of a particular idea. This explains why he has no record of entrepreneurial failure.
Every new development made by scientists in the field of cancer treatment brings excitement to Scott. He told Ideamensch that as new treatment methodologies crop up, cancer patients will continue to enjoy prolonged lives than it is today.